Alnylam Pharmaceuticals, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
243.09
|
|
Average Rating
|
4.04
|
|
# Strong Buys
|
10
|
|
# Buys
|
6
|
|
# Holds
|
9
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-1.77
|
-3.32
|
-1.55
|
-87.57%
|
|
2022-06-30
|
-1.63
|
-2.29
|
-0.66
|
-40.49%
|
|
2022-03-31
|
-1.84
|
-2.00
|
-0.16
|
-8.70%
|
|
2021-12-31
|
-1.54
|
-2.16
|
-0.62
|
-40.26%
|
|
2021-09-30
|
-1.57
|
-1.72
|
-0.15
|
-9.55%
|
|
2021-06-30
|
-1.61
|
-1.61
|
0.00
|
0.00%
|
|
2021-03-31
|
-1.73
|
-1.71
|
0.02
|
1.16%
|
|
2020-12-31
|
-1.71
|
-2.09
|
-0.38
|
-22.22%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-7.61
|
|
2021-12-31
|
-7.20
|
|
2020-12-31
|
-7.45
|
|
2019-12-31
|
-8.14
|
|
2018-12-31
|
-7.56
|
|
2017-12-31
|
-5.41
|
|
2016-12-31
|
-4.79
|
|
2015-12-31
|
-3.45
|
|
2014-12-31
|
-1.83
|
|
2013-12-31
|
-1.44
|
|
2012-12-31
|
-1.34
|
|
2011-12-31
|
-1.35
|
|
2010-12-31
|
-1.03
|
|
2009-12-31
|
-1.15
|
|
2008-12-31
|
-0.64
|
|
2007-12-31
|
-2.23
|
|
2006-12-31
|
-1.10
|
|
2005-12-31
|
-1.93
|
|
2004-12-31
|
-1.72
|